Advances in Next Generation Sequencing (NGS) are driving improvements in detection, treatment and routine monitoring of cancer. Faster and more accurate assays will ultimately lead to better outcomes for patients. Hear from key opinion leaders in the cancer research and clinical oncology field, and learn how they overcome their research hurdles using Twist’s robust and effective NGS target enrichment solutions.

DNA methylation is a key epigenetic signal that helps control gene expression. It is often misregulated in cancers and thus has become an important marker in oncology research. Most current methods for methylation detection involve differential conversion of bases (e.g., C to T and meC to C) during library preparation. These methods can have batch effects that are difficult to control and thus researchers could benefit from a set of known standards that can be used to calibrate methylation experiments. Twist has developed a set of methylation controls for just that purpose. Our controls can be spiked into samples to calibrate methylation measurements. By using a set of 48 orthogonal sequences with different sequences, numbers of CpG sites, and levels of methylation, researchers can quantitatively assess conversion efficiencies.

Learn about capture sequencing with Twist’s RNA Exome panel using a novel design strategy.